TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04247490

Intervention type: DIAGNOSTIC_TEST
Intervention: pediatric AIH
Description: pediatric patients with clinical, laboratory (transaminase and IgG increase), instrumental (ultrasound, liver biopsy) characteristics
Study: NCT01751412

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Study: NCT02079792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lying Head Back Position
Description: Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head Down and Forward Position
Description: Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards.
Study: NCT04110028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Nicotinamide riboside in different doses
Study: NCT00723099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV
Study: NCT00723099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo umbilical cord blood transplant
Study: NCT02224963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive Problem-Solving Training
Description: Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life and Health Review
Description: Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
Study: NCT02572947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Study: NCT02579798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEP (positive end-expiratory pressure)
Study: NCT04110028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Nicotinamide riboside in different doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Nicotinamide riboside in different doses
Study: NCT02579798

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP (positive end-expiratory pressure)
Study: NCT04110028

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04018248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR101801 (Phase Ia)
Description: Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR101801 (Phase Ib)
Description: Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.
Study: NCT00525772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclesonide
Description: low dose- 50ug and 200ug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclesonide
Description: high dose- 100ug and 400ug
Study: NCT03962296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitis vinifera extract
Description: Three daily oral doses of 50mg tablets of Vitis vinifera extract(Entelon®, Hanlim Pharm, Seoul, South Korea) were administered to patients in this group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Dobesilate
Description: Three daily oral doses of 50mg tablets of Calcium Dobesilate(Doxium®, Ilsung Pharm, Seoul, South Korea) were administered to patients in this group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets lacked Vitis vinifera extract or calcium dobesilate, but their appearance was identical to those of the study group tablets.
Study: NCT05680454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
Description: For Low-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6. For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine
Description: A 3-dose regimen administered at months 0, 2 and 6.
Study: NCT04110028

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00936754

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
Study: NCT00507429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA4P
Description: CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 200mg/m squared on Day 1
Study: NCT00730522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPP-109 vigabatrin
Description: tablets, bid for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: tablets, bid, 12 weeks
Study: NCT02391428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood test
Description: Blood test: Small volume (3 ml) of blood will be taken by venipuncture into ethylenediaminetetraacetic acid (EDTA) tube.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood test
Description: Blood test: Small volume (3 ml) of blood will be taken by venipuncture into ethylenediaminetetraacetic acid (EDTA) tube.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega3 capsules
Description: Only ADHD children will be given a supply of omega3 capsules (containing 400 mg EPA and 200 mg DHA)
Study: NCT01883089

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Enhancement Therapy
Study: NCT03692676

Intervention type: DEVICE
Intervention: Spiriva Respimat
Description: soft-mist inhaler
Study: NCT03557138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside
Description: positron emission tomography and magnetic resonance imaging (PET/MRI) of kidneys of diabetic patients using alpha-Methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside (Me4FDG)
Study: NCT00521248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms
Study: NCT00507429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: 6 AUC on Day 1 following paclitaxel
Study: NCT00521248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral morphine solution
Description: 0.4 mg/kg/day morphine every 4 hours
Study: NCT03604120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preoxygenation with high flow therapy by nasal cannula
Description: Preoxygenation during 4 minutes with High Flow Nasal Cannula (60l/min FiO2 = 1) before fiber-optic or laryngoscopic intubation. The device will be maintained in place throughout the intubation procedure in order to achieve oxygenation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Preoxygenation by standard Facial mask
Description: * For Fiber-optic intubation: patients will receive a 4 minutes FIBROXY facial mask preoxygenation with FiO2=100%. The FIBROXY facial mask will be maintained in place during the intubation procedure.~* For Laryngoscopic intubation: patients will receive a 4 minutes standard facial mask preoxygenation with FiO2=100%. The standard facial mask will be removed after crash induction to proceed to intubation.
Study: NCT04843163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAMI Basics
Description: NAMI Basics is a peer service program for caregivers of children with mental health needs. It was created by the National Alliance on Mental Illness (NAMI) and was adapted from their empirically supported model for caregivers of adult children with mental illness (Family-to-Family). The child-focused intervention, NAMI Basics, is a six-class curriculum focused on increasing caregiver knowledge about mental illness, empowering parents to advocate for their children across service systems, and introducing skills that assist in family problem-solving and communication (Brister et al., 2012). The program is currently available widely throughout the U.S. through certified trainers who volunteer with local NAMI affiliates and is provided free of charge to caregivers in a non-stigmatizing community setting (e.g., local school, church, community center). It is open to all caregivers, regardless of mental health diagnosis or time within a treatment system.
Study: NCT02324998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: PARP Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: PARP Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Gonadotrophin releasing hormone blocker
Study: NCT00602914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: The micronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the skin). In this study the MicronJet will be used to inject insulin vs. a convention needle injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: The micronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the skin). In this study the MicronJet will be used to inject insulin vs. a convention needle injection.
Study: NCT03718455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axillary Magseed
Description: The Magseed will replace the investigators' current clinical practice of using radioactive seeds in women receiving neoadjuvant chemotherapy.
Study: NCT02275923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal LINQ™ Insertable Cardiac Monitor
Description: Insertable cardiac monitor
Study: NCT00602914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: MicronJet, Intradermal Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: MicronJet, Intradermal Injection
Study: NCT02575898

Intervention type: OTHER
Group type: OTHER
Intervention: First Session
Description: Creative Practice and Positive Re-enforcement

Intervention type: OTHER
Group type: OTHER
Intervention: Second Session
Description: Disease Related

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Third through Sixth Sessions
Description: Life Review and Legacy
Study: NCT01368445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine hydrochloride 0.15% Nasal Spray
Description: 1644 mcg, 2 sprays per nostril twice daily AM \& PM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: azelastine hydrochloride 0.15% Nasal Spray
Description: 1644 mcg, 2 sprays per nostril twice daily AM \& PM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine hydrochloride 0.15% and Placebo
Description: 822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: azelastine hydrochloride 0.15% and Placebo
Description: 822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine 0.1%, Nasal Spray
Description: 1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM \& PM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azelastine 0.1%, Nasal Spray
Description: 1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM \& PM)
Study: NCT02833441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Study: NCT03982043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text2Connect
Description: Text2Connect is a personalized text messaging intervention for patients and parents that targets self-identified barriers to engaging in treatment to increase the likelihood that a depressed or suicidal patient will initiate recommended services.
Study: NCT03699280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Oculus Go VR device
Study: NCT03430479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A
Description: Radiation + Nivolumab + hormone therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A
Description: Radiation + Nivolumab + hormone therapy
Study: NCT01513265

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical care plan, mostly based on the RASP
Description: Drug use of subjects enrolled in this arm will be systematically evaluated by a clinical pharmacist, using the RASP list. Potentially inappropriate drug use will be pointed out to the treating physician. The pharmaceutical advice is not limited to the RASP list. Any actual change in drug prescription will be decided by the treating physician based upon comprehensive medical evaluations in each individual patient.
Study: NCT03722758

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectrum TPH3
Description: tooth restoration with two different restorative materials

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectrum TPH3
Description: tooth restoration with two different restorative materials

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Riva LC
Description: tooth restoration with two different restorative materials

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Riva LC
Description: tooth restoration with two different restorative materials
Study: NCT03159234

Intervention type: RADIATION
Group type: OTHER
Intervention: fetal lung volume
Description: the best method for measurement of fetal lung volume is by the rotational technique in which each lung is obtained by serial contouring of the pulmonary area after rotating the volumetric image.this is more recent method seems to have advantages allowing finer contouring of the lung and subsequent modification of the contour as well as being better able to estimate the volumes of irregular and small lung as in congenital diaphragmatic hernia

Intervention type: RADIATION
Group type: OTHER
Intervention: pulmonary artery resistance index
Description: Women placed in semirecumbent position and an axial plane through the fetal thorax to achieve 4 chamber view of the heart. The main pulmonary artery was followed to the point where it divides into right and left branches by rotating the transducer from the 4 chamber view to the short axis view of the heart. Pulsed and colour Doppler was used. The fetal pulmonary artery flow waveform measurements was taken within the proximal portion of the main pulmonary artery
Study: NCT01379976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcarnitine
Description: ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal.
Study: NCT01141023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaTscan
Study: NCT03159234

Intervention type: RADIATION
Group type: OTHER
Intervention: Fetal adrenal gland volume:
Description: the adrenal gland has a characteristic sonographic appearance; each limb is seen as a long anechoic structure with a thin, echogenic line within its center . Both limbs can sometimes be seen in the coronal plane, and if so there is a strong echogenic line between limbs (probably fat). On the basis of pathologic and histologic studies , we believe the anechoic bulk of the gland represents the fetal zone of the cortex, while the central echogenic core is the medulla.
Study: NCT04064411

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: abaloparatide
Description: Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: abaloparatide solid microstructured transdermal system
Description: Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto a sMTS array for transdermal administration of abaloparatide.
Study: NCT03634995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days
Study: NCT02746263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Patient controlled analgesia
Study: NCT03634995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT02746263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Patient controlled analgesia
Study: NCT03634995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT02682342

Intervention type: OTHER
Intervention: 75 g glucose solution
Description: This is the same as the standard oral glucose challenge dose and route given clinically
Study: NCT03543969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 450 mg encorafenib daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: 45 mg binimetinib daily by mouth
Study: NCT04635423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: 9-valent vaccine, HPV 6/11/16/18/31/33/45/52/58, L1 virus-like particle (VLP) 30/40/60/40/20/20/20/20/20 mcg per dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (NaCL)
Study: NCT02201498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomies with Formocresol/OZE and Biodentine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomies with Formocresol/OZE and Biodentine
Study: NCT02123992

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elevate Apical and Posterior

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Native Tissue Repair for pelvic organ prolapse
Study: NCT00958256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m\^2 given intravenously over 3-5 seconds at the end of infusion of Rituximab on Day 1 of every cycle, then on Days 4, 8 and 11 of every cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 given intravenously over 6-8 hours on Day 1 of every 21-day study cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenously over 3 hours 2 times each day (6 hours total each day) on Days 2, 3, and 4 of every cycle
Study: NCT03543969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg Nivolumab IV every 2 weeks
Study: NCT00958256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 600 mg/m\^2 intravenous continuous infusion (IVCI) over 24 hours daily for 3 days, 1 hour prior to Cyclophosphamide and complete by 12 hours after last dose of Cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 micrograms/kg subcutaneously daily starting 24-36 hours for 7 days after last dose of Bortezomib until granulocytes are more than 4 x 103/dl.
Study: NCT03912207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
Study: NCT03543969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: 240 mg Nivolumab IV every 2 weeks
Study: NCT02051374

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression followed by fusion with instrumentation